ArticleGut pathogens2019
Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma.
Article in Gut pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
134 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The effects of helminth infections on the human gut microbiome: a systematic review and meta-analysis.Frontiers in microbiomes · 2023Pooled it
- Meta-analysis defines predominant shared microbial responses in various diseases and a specific inflammatory bowel disease signal.Genome biology · 2022Pooled it
- Gut microbiota modulation of gastrointestinal cancers: from dysbiosis signatures to therapeutic interventions.Acta pharmacologica Sinica · 2026Review
- Immune fitness and biomarkers of immune function: Relationships with the oral and gut microbiome composition.Brain, behavior, & immunity - health · 2026Article
- The gut-liver axis: exploring microbial dysbiosis and specific biomarkers in hepatocellular carcinoma.AMB Express · 2026Article
- HBV and the Microbiome-PubMed Database Literature Review.Infectious disease reports · 2026Review
- How the gut microbiome affects the immunotherapy response in hepatocellular carcinoma.Cancer biology & medicine · 2026Review
- Gut microbiota-metabolism-immunity axis: a novel perspective of traditional Chinese medicine in hepatocellular carcinoma treatment.Chinese medicine · 2026Article
- Insights into the influencing factors of fecal gut microbiota in hepatocellular carcinoma.World journal of gastroenterology · 2026Article
- Sequential hepatectomy for hepatocellular carcinoma with inadequate future-liver-remnant after portal vein ligation in combination with apatinib plus camrelizumab (PLACES): a single-arm prospective pilot study.Hepatobiliary surgery and nutrition · 2026Article
- Bibliometric Analysis of Gut Microbiota and Hepatocellular Carcinoma: Research Trends and Frontiers.Journal of hepatocellular carcinoma · 2026Article
- Gut Microbiota in Hepatocellular Carcinoma: Etiology-Specific Evidence, Mechanisms, and Translational Challenges.Journal of hepatocellular carcinoma · 2026Review
- Gut microbial signatures of advanced hepatocellular carcinoma and their potential diagnostic value.Frontiers in microbiology · 2026Article
- The landscape of gut microbiota in hepatocarcinogenesis: a comprehensive review of pathogenesis and therapeutic interventions.International journal of surgery (London, England) · 2026Review
- Ginseng-derived exosome-like nanovesicles protect against liver fibrosis by regulating TIMP2 pathways and gut dysbiosis.Asian journal of pharmaceutical sciences · 2025Article
- Gut microbiome dysbiosis in hepatocellular carcinoma patients with persistent HCV viremia versus viral clearance: a cross-sectional study.Gut pathogens · 2025Article
- Hepatitis B Virus-Related Liver Disease and Gut Microbiota: An Updated Review.Microorganisms · 2025Review
- Gut microbiota and bile acids changes in MASLD mice model with hepaticActa biochimica et biophysica Sinica · 2025Article
- The microbiome in cancer.iMeta · 2025Review
- Characteristics and potential diagnostic value of gut microbiota in ovarian tumor patients.Scientific reports · 2025Article
74 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe onset of hepatocellular carcinoma (HCC) ranked fifth malignancies all over the world. Increasing evidences showed that the distribution of HCC was related to the incidence of chronic hepatitis B virus (HBV) infection and other factors, such as alcoholism, aflatoxin B1 ingestion and obesity. Recent studies demonstrated that gut dysbiosis plays an important role in liver diseases. However, the researches on gut microbiota of HBV and non-HBV non-HCV related HCC have not been reported. In this study, we investigated the differences between the gut microbiota of HBV related HCC (B-HCC) and non-HBV non-HCV related HCC (NBNC-HCC), finally found some potential bacteria, linking different pathological mechanism of both types of HCCs.
resultsWe carried out 16S rRNA analyses in a cohort of 33 healthy controls, 35 individuals with HBV related HCC (B-HCC) and 22 individuals with non-HBV non-HCV (NBNC) related HCC (NBNC-HCC). We found that the species richness of fecal microbiota of B-HCC patients was much higher than other two groups. Interestingly, the feces of NBNC-HCC patients harbored more potential pro-inflammatory bacteria (
conclusionsOur study indicated that B-HCC and NBNC-HCC patients showed differential abundance of bacteria involved in different functions or biological pathways. We suggested the modification of specific gut microbiota may provide the therapeutic benefit for B-HCC and NBNC-HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.